The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Serum NFL discriminates Parkinson disease from atypical parkinsonisms
Open accessAbstract
Objective To investigate the diagnostic value of serum neurofilament light chain (NFL) in patients with clear signs of parkinsonism but whose specific diagnosis was yet uncertain. Methods Serum samples were collected from patients with clear signs of parkinsonism but with uncertain diagnosis at the inclusion. Clinical diagnoses of Parkinson disease (PD) and atypical parkinsonism disorders (APDs) were established after 3 years of follow-up and updated again after a maximum of 12 years in case longer follow-up data were available. Serum NFL was quantified by single molecule array in patients with PD (n = 55) and APD (n = 29, multiple system atrophy = 22, progressive supranuclear palsy = 7) and 53 nonneurologic controls. Results Serum NFL levels were elevated and differentiated the APD group (mean 23.8 ± 10.3 ng/L) from PD (mean 10.4 ± 4.9 ng/L) and controls (mean 11.5 ± 6.5 ng/L, p < 0.0001) with accuracy levels up to 91% (sensitivity = 86% and specificity = 85%). Serum NFL strongly correlated with CSF NFL levels (r = 0.72, p < 0.0001) in all groups and with age in PD (r = 0.78, p < 0.0001) and controls (r = 0.66, p < 0.0001). In our cohort, the probability of having APD was 76% (positive predictive value) and of having PD 92% (negative predictive value). Conclusion Serum NFL levels are markedly elevated in APD compared to PD and discriminate APDs from PD with high accuracy. Serum NFL may be a useful clinical biomarker to identify APD, even at stages when clinical symptoms are not yet conclusive. Classification of evidence This study provides Class II evidence that serum NFL levels accurately discriminate APDs from PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“We observed strong correlations between CSF and serum levels for NfL, as it has been previously reported [31, 88, 89].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Self-citationSecond consensus statement on the diagnosis of multiple system atrophy
Gilman, S., Wenning, G. K., Low, P. A., Brooks, D. J., Mathias, C. J., Trojanowski, J. Q., Wood, N. W., Colosimo, C., Dürr, A., Fowler, C. J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000324625.00404.15 · Cited by 3,140
Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
Höglinger, G. U., Respondek, G., Stamelou, M., Kurz, C., Josephs, K. A., Lang, A. E., Mollenhauer, B., Müller, U., Nilsson, C., Whitwell, J. L., et al. (2017) · Movement Disorders · doi:10.1002/mds.26987 · Cited by 2,434
The Mini-Mental State Examination
Folstein, M. F. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790060110016 · Cited by 2,016
Scale for the assessment and rating of ataxia: Development of a new clinical scale
Schmitz-Hübsch, T., du Montcel, S. T., Baliko, L., Berciano, J., Boesch, S., Depondt, C., Giunti, P., Globas, C., Infante, J., Kang, J. S., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000219042.60538.92 · Cited by 1,967
Criteria for the diagnosis of corticobasal degeneration
Armstrong, M. J., Litvan, I., Lang, A. E., Bak, T. H., Bhatia, K. P., Borroni, B., Boxer, A. L., Dickson, D. W., Grossman, M., Hallett, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31827f0fd1 · Cited by 1,904
Parkinsonism: Onset, progression, and mortality
Hoehn, M., & Yahr, M. (2011) · Neurology · doi:10.1212/01.wnl.0000405146.06300.91 · Cited by 1,888
The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations
Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease (2003) · Movement Disorders · doi:10.1002/mds.10473 · Cited by 1,811
Cited by
Sorted by citations
Items 101–152 of 152
An emerging biomarker for dopaminergic cell loss
Verbeek, M. M., & Bloem, B. R. (2023) · Nature Aging · doi:10.1038/s43587-023-00501-2 · Cited by 6
Self-citationVervuurt, M., Kuiperij, H. B., de Kort, A. M., Kersten, I., Klijn, C. J. M., Schreuder, F. H. B. M., & Verbeek, M. M. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01473-0 · Cited by 5
Self-citationYu, Z., Su, D., Li, S., Lin, S., Ren, K., & Feng, T. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00558-0 · Cited by 5
Blood neurofilament light chain in Parkinson disease and atypical parkinsonisms
Wang, H., Wang, W., Shi, H., Han, L., & Pan, P. (2020) · Medicine · doi:10.1097/md.0000000000021871 · Cited by 5
Liu, S., Zhu, X., Pu, H., Chen, Y., Zhu, X., Chen, L., Zhang, C., Zhang, R., & Zhong, P. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-02940-0 · Cited by 4
Rissardo, J. P., Rashidi, M., Rashidi, F., Hmedat, K. I., Khalil, I., Moharam, H., Bahar, M., Dway, A., Prathiraja, O., Caprara, A. L. F., et al. (2025) · Cureus · doi:10.7759/cureus.88487 · Cited by 4
Li, C., Fan, S., Chen, P., Chang, Y., Lan, M., Wu, Y., Hsiao, I., Chiang, H. L., Chen, C., Lee, T.-L., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000214406 · Cited by 4
Cerebrospinal fluid and blood levels of neurofilament light chain in Parkinson disease
Wang, H., Wang, W., Shi, H., Han, L., & Pan, P. (2020) · Medicine · doi:10.1097/md.0000000000021458 · Cited by 4
Potential Protein Blood-based Biomarkers in Different Types of Dementia: A Therapeutic Overview
Manzine, P. R., Vatanabe, I. P., Grigoli, M. M., Pedroso, R. V., Monteiro, M. P. A. O., de Oliveira, D. D. S. M. S., Nascimento, C. M. C., Peron, R., Orlandi, F. D. S., & Cominetti, M. R. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220408124809 · Cited by 4
Serum Neurofilament light chain predicts autonomic symptoms in early Parkinson’s disease
Li, L., Yang, Y., Zhang, E., Chen, H., & Zhao, Z. (2025) · Neurodegenerative Disease Management · doi:10.1080/17582024.2025.2554531 · Cited by 3
Early detection of Parkinson’s disease via aptamer-CRISPR platform
Madhusudhan, K., Padmanaban, A., & Parvathi, V. D. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.09.027 · Cited by 3
Massey, Q., Nihoyannopoulos, L., Zeidman, P., Warner, T. T., Bhatia, K. P., Gandhi, S., & Lambert, C. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01157-y · Cited by 3
Pérez‐Soriano, A., Painous, C., Fernandez, M., Perez-Montesino, J., de Mena, L., Zaro, I., Cámara, A., & Compta, Y. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-03070-3 · Cited by 4
Plasma NFL, GFAP, sTREM2, pTau231, and clinical severity in progressive supranuclear palsy
Lee, S., Kim, H., Kim, R., Jin, B., Kim, S., Ha, S. H., Shin, J. H., Jeon, B., Kim, H.-J., & Lee, J.-Y. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13570-7 · Cited by 3
Mi, F., Wang, Y., Chai, W., Chen, Y., & Yin, X. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1295904 · Cited by 3
Neurofilaments in neurologic disease
Mousele, C., Holden, D., & Gnanapavan, S. (2024) · Advances in clinical chemistry · doi:10.1016/bs.acc.2024.06.010 · Cited by 3
Schneider, V., Véjux, A., Nury, T., Dupont, G., de Barros, J.-P. P., Lakomy, D., Lizard, G., & Moreau, T. (2023) · Revue Neurologique · doi:10.1016/j.neurol.2022.12.015 · Cited by 3
Serum neurofilament light chain in LRRK2 related Parkinson’s disease: A five years follow-up
Nabizadeh, F., Mohamadzadeh, O., Hosseini, H., Rasouli, K., & Afyouni, N. E. (2023) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2023.01.015 · Cited by 3
Multiple system atrophy – Are cerebrospinal fluid cytokines reliable potential diagnostic marker?
Fellner, L., & Wenning, G. K. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.09.019 · Cited by 3
Makanjuola, A., Taiwo, F., Yaria, J. O., Akinyemi, R., & Ogunniyi, A. O. (2021) · Journal of Global Medicine · doi:10.51496/jogm.v1.35 · Cited by 2
Körtvelyessy, P., Arslan, B., Nietiet, J., Leithner, C., Hühnchen, P., Boehmerle, W., Endres, M., Ploner, C. J., Audebert, H. J., Hahn, K., et al. (2025) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2025.123669 · Cited by 2
Kim, K., & Bhaskar, S. M. M. (2026) · European Journal of Neuroscience · doi:10.1111/ejn.70381 · Cited by 2
Advances in biomarkers for Parkinson’s disease: from molecular pathology to precision diagnostics
Li, X., Chen, H., Wang, X., Hu, Y., Yang, Z., & Wei, M. (2026) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2500789 · Cited by 2
Atypical parkinsonism, parkinsonism-plus syndromes and secondary parkinsonian disorders
Jankovic, J. J., Hallett, M., Okun, M. S., Comella, C., Fahn, S., & Goldman, J. G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-31071-0.00009-3 · Cited by 2
Neurofilament light chain for classifying the aetiology of alteration of consciousness
Ongphichetmetha, T., Thanapornsangsuth, P., Luechaipanit, W., Loymunkong, N., Rattanawong, W., Hiransuthikul, A., Supharatpariyakorn, T., Sriswasdi, S., & Hemachudha, T. (2023) · Brain Communications · doi:10.1093/braincomms/fcad278 · Cited by 2
Luca, D. G. D., & Lang, A. E. (2021) · Brain · doi:10.1093/brain/awab115 · Cited by 2
High serum neurofilament light chain predicts a worse fate in early parkinsonism
Akhtar, R. S., & Mano, T. (2019) · Neurology · doi:10.1212/wnl.0000000000007194 · Cited by 2
Gomez‐Virgilio, L., Gutierrez‐Malacara, A., Rivera‐Osorio, J., Silva‐Lucero, M., Padilla-Mendoza, J. R., Gómez-Ramírez, D. E., & Cárdenas-Aguayo, M. D. C. (2024) · Gaceta Médica de México · doi:10.24875/gmm.m24000930 · Cited by 1
Han, J., Sun, M., Yang, J., & An, Y. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08503-1 · Cited by 1
Jin, B., Kim, S., Lee, S., Ha, S. H., Woo, K. A., Shin, J. H., Jung, K., & Kim, H. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13559-2 · Cited by 1
Ti, K., Zhao, Y., Tan, E., & Ma, D. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146254 · Cited by 1
Author response: Blood NfL: A biomarker for disease severity and progression in Parkinson disease
Lin, C., & Chiu, M. (2020) · Neurology · doi:10.1212/wnl.0000000000010664 · Cited by 1
Reader response: Blood NfL: A biomarker for disease severity and progression in Parkinson disease
van Rumund, A., Marques, T. M., Esselink, R. A. J., Bloem, B. R., & Verbeek, M. M. (2020) · Neurology · doi:10.1212/wnl.0000000000010668
Self-citationWang, H., Wang, W., Shi, H., & Han, L. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.05.024
Jankovic, J. J., Hallett, M., Okun, M. S., Comella, C., Fahn, S., & Goldman, J. G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-31071-0.00004-4
Search for Molecular Biomarkers of Parkinson’s Disease. New Tissues and Methods
Račay, P. (2023) · Acta Medica Martiniana · doi:10.2478/acm-2023-0003 · Cited by 1
Massey, Q., Nihoyannopoulos, L., Zeidman, P., Warner, T. T., Bhatia, K. P., Gandhi, S., & Lambert, C. (2023) · medRxiv · doi:10.1101/2023.12.12.23299891
Massey, Q., Nihoyannopoulos, L., Zeidman, P., Warner, T. T., Bhatia, K. P., Gandhi, S., & Lambert, C. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4865047
Translational Value of CSF and Serum Markers
Schiffer, J., & Groppa, S. (2024) · Neuromethods · doi:10.1007/978-1-0716-4083-8_8
Schwahn, J., Hebestreit, S., Kosche, O., Steinacker, P., Sandikci, V., Winzer, I., Hesebeck‐Brinckmann, J., Bachhuber, F., Valkadinov, I., Nittka, S., et al. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf388
Self-citationVervuurt, M., Kuiperij, H. B., de Kort, A. M., Kersten, I., Klijn, C. J. M., Schreuder, F. H. B. M., & Verbeek, M. M. (2024) · Figshare · doi:10.6084/m9.figshare.25824651
Self-citationWolff, A. W., Feneberg, E., Shakhtour, J., Steiger, K., Schmid, R. M., Haller, B., Reinhardt, N., Middelhoff, M. A., Schult, D., & Lingor, P. (2026) · PLoS ONE · doi:10.1371/journal.pone.0340182
Plasma proteomic trajectories before the onset of neurodegenerative diseases
Zhang, Z., Fan, R., Jing, S., Liu, S., Liu, L., Que, W., Lu, D., Gan, Y., & Xiao, F. (2026) · Neurodegenerative Disease Management · doi:10.1080/17582024.2026.2646760
Priya, Mittal, R., Banerjee, J., & Dixit, A. B. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.02.006
Rajesh, N., Jasmine, R., Joji, R., Sivakumar, S., & Francis, D. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.05.009
Samaniego, D., Enríquez-Calzada, S., Domingo, L., Armengol, M., Camprodón-Gómez, M., Melgarejo, L., Arrúe-Gonzalo, M., Miret-Milian, M., González, V., Belmonte, S., et al. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1858685
Harris, G. A., Barnhard, L., Brummet, J., & Diaz, K. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1893149
Alshammari, N., Hassan, R., Patel, M. B., & Adnan, M. (2026) · Pharmaceuticals · doi:10.3390/ph19091326
Research Progress of Oxidative Stress Biomarkers in the Early Screening of Parkinson’s Disease
钟, 敬. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1693173
Metadata
- Authors
- Marques, T. M., van Rumund, A., Oeckl, P., Kuiperij, H. B., Esselink, R. A. J., Bloem, B. R., Otto, M., & Verbeek, M. M.
- Affiliations
- Radboud University Nijmegen (NL)
- From the Department of Neurology (T.M.M., A.v.R., H.B.K., R.A.J.E., B.R.B., M.M.V.), Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen; Department of Laboratory Medicine (T.M.M., H.B.K., M.M.V.), Radboud University Medical Center, Nijmegen; Parkinson Center Nijmegen (T.M.M., A.v.R., R.A.J.E., B.R.B., M.M.V.), the Netherlands; and Department of Neurology (P.O., M.O.), Ulm University Hospital, Germany.
- ORCID
- Venue
- Neurology
- Published
- 2019-03-26
- Volume
- 92
- Issue
- 13
- Pages
- e1479-e1486
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2919112269
- Cited by
- 153
- References
- 45
- Citations by year
- 2026: 12 · 2025: 21 · 2024: 21 · 2023: 23 · 2022: 22 · 2021: 31 · 2020: 18 · 2019: 5
- FWCI
- 12.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- neurofilament light chain, serum biomarkers, Parkinson's disease, atypical parkinsonism, multiple system atrophy, progressive supranuclear palsy, differential diagnosis, diagnostic accuracy
- MeSH terms
- Aged, Diagnosis, Differential, Female, Humans, Male, Middle Aged, Parkinson Disease, Sensitivity and Specificity, Supranuclear Palsy, Progressive, Case-Control Studies, Neurofilament Proteins, Multiple System Atrophy, Parkinsonian Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
